AGA seeks damages as Occlutech shuts doors
This article was originally published in Clinica
Executive Summary
AGA Medical has initiated proceedings in a German insolvency court to recover damages from rival Occlutech, which has recently closed down its operations. The two companies had a two-year patent dispute that drew to a close earlier in January, after a German court ruled that Occlutech infringed patents held by Minneapolis, Minnesota-based AGA (see Clinica No 1332, p 19). As a result, Occlutech was forced to stop selling its flagship Figulla occluder product and pay AGA damages. Occlutech, of Helsingborg, Sweden, has since terminated all manufacturing and sales and its CEO has resigned, according to AGA. The latter said it has calculated and notified Occlutech the amount of damages that it is seeking.